advanced influenza treatment
play

Advanced Influenza Treatment Options for the 2020-2021 Season - PowerPoint PPT Presentation

Reducing the Risk: Advanced Influenza Treatment Options for the 2020-2021 Season Learning Objectives Identify patients at high risk for complications of influenza Select influenza treatment for adult patients at high risk of


  1. Reducing the Risk: Advanced Influenza Treatment Options for the 2020-2021 Season

  2. Learning Objectives • Identify patients at high risk for complications of influenza • Select influenza treatment for adult patients at high risk of complications based on current recommendations and evidence • Individualize influenza treatment in pediatric patients based on current recommendations 2

  3. Epidemiology and Burden of Seasonal Influenza in the US • Annual Estimates by the CDC From 10 Influenza Rates of serious illness and death Seasons (2010-2011 through 2019-2020)* from seasonal influenza are highest in persons >65 years, in 9.3 to 45 million illnesses children <2 years, and in anyone with medical conditions at increased risk for complications 14.2 to 21 million outpatient medical visits • During the 2017-2018 flu season, influenza is estimated to have 140,000 to 810,000 hospitalizations killed 61,000 people in the United States, more than any other year since 2010 12,000 to 61,000 deaths *Data for 2017-2018, 2018-2019, 2019-2020 are preliminary estimates. Centers for Disease Control and Prevention. cdc.gov/flu/about/burden/index.html. Accessed Nov 2, 2020; Centers for Disease Control and Prevention. gis.cdc.gov/GRASP/Fluview/FluHospRates.html. Accessed Nov 2, 2020; Rolfes MA, et al. Influenza Other Respir Viruses. 2018;12:132-137. 3

  4. Pneumonia, Influenza, and COVID-19 Mortality: 2017-2020 28 18,000 Number of influenza coded deaths 26 Number of COVID-19 coded deaths 16,000 24 % of All Deaths Due to PIC % of deaths due to PIC 22 14,000 Number of Deaths Seasonal baseline 20 Epidemic threshold 12,000 18 16 10,000 14 Epidemic Threshold 8000 12 10 6000 8 4000 6 4 2000 Seasonal baseline 2 0 0 40 50 10 20 30 40 50 10 20 30 40 50 10 20 30 40 50 10 20 30 40 2017 2018 2019 2020 MMWR Week COVID-19 = Coronavirus disease 2019; PIC = pneumonia, influenza, or COVID-19. 4 Centers for Disease Control and Prevention. www.cdc.gov/flu/weekly/overview.htm#anchor_1539281356004. Accessed Nov 2, 2020.

  5. Pandemics: Influenza and COVID-19 Common Name Year Virus Estimated No. of Deaths Spanish flu 1918 H1N1 50 million-100 million Asian flu 1958 H2N2 1 million-2 million Hong Kong flu 1968 H3N2 500,000-2 million H1N1 pandemic 2009 H1N1 151,700-575,400 COVID-19 2020 SARS-CoV-2 2,342,648* (by Jan 1, 2021) *Projected as of Oct 2, 2020. Dawood FS, et al. Lancet Infect Dis. 2012;12:687-695; Johns Hopkins University & Medicine. coronavirus.jhu.edu/map.html. Accessed Nov 2, 2020; Johnson NP, et al. Bull Hist Med. 2002;76:105-115; Saunders-Hastings PR, et al. Pathogens . 2016;5:66; Simonsen L, et al. PLoS Med. 2013;10:e1001558; Taubenberger JK, et al. Emerg Infect Dis. 2006;12:15-22; University of Washington Institute for Health Metrics and Evaluations. 5 covid19.healthdata.org/global?view=total-deaths&tab=trend. Accessed Nov 2, 2020.

  6. Influenza Virus • The family Orthomyxoviridae has 3 genera, or types, Hemagglutinin NA NA Hemagglutinin that infect humans: influenza viruses A, B, and C NS 2 NS2 • Influenza A virus subtypes are based on specific HA and NA glycoproteins that they express − 18 HAs (H1-H18) Lipid Lipid − 11 NAs (N1-N11) bilayer bilayer − Potential for 144 HA and NA combinations (some HAs and NAs cannot work together) Ion Ion • Birds are reservoir for 16 HA and 9 NA subtypes channel channel Matrix Matrix protein protein Negative-sense HA = hemagglutinin; NA = neuraminidase; NS = nonstructural protein; RNA = ribonucleic acid; ss = single stranded. ssRNA 6 Clancy S. Nature Education . 2008;1:83; Vemula SV, et al. Viruses. 2016;8:96.

  7. Case Study: Victor, a 55-Year-Old Male of Hispanic and Native-American Descent • Victor visits your primary care practice in November for an annual checkup • Height: 5 ft 8 in • Weight: 265 lb (BMI = 40.3 kg/m 2 ) • Blood pressure: 132/79 mm Hg (controlled with medication) • Unvaccinated against influenza and skeptical about the vaccine ⎻ He received the vaccine last year and “got the flu” the day after • You recommend influenza vaccination, but he refuses 7 7

  8. Focus on Patients at Higher Risk for Influenza Complications Demographic factors Chronic Medical Conditions • Adults aged ≥65 years • Asthma • • Children <5 years (highest risk in children Neurologic and neurodevelopmental conditions <2 years, especially if <6 months) • Blood disorders (eg, sickle cell disease) • Pregnant women and women up to 2 • Certain types of cancer (lymphoma and leukemia) and cancer weeks postpartum survivors • American Indians/Alaska Natives • Chronic lung disease (eg, COPD, cystic fibrosis) • Residents of nursing homes and other • Diabetes long-term care facilities • Kidney disorders • Liver disorders • Morbid obesity (BMI ≥40 kg/m 2 ) • <19 years of age and on long-term aspirin- or salicylate-containing medications • Compromised immune system or on immunosuppressive therapies 8 Centers for Disease Control and Prevention . cdc.gov/flu/highrisk/index.htm. Accessed Nov 2, 2020.

  9. Influenza Vaccines: 2020-2021 Influenza Season Manufacturing Process Age Indication Route Formulations Egg based † ≥6 months IIV4 standard dose IM Prefilled syringe, MDV* ≥4 years IIV4 standard dose Cell culture based IM Prefilled syringe, MDV* Egg based† ≥65 years IIV4 high dose IM Prefilled syringe Egg based † ≥65 years IIV4 standard dose with IM Prefilled syringe MF59 adjuvant Egg based † ≥65 years IIV3 standard dose with IM Prefilled syringe MF59 adjuvant ≥18 years RIV4 Recombinant HA IM Prefilled syringe LAIV4 ‡ Egg based † 2 to 49 years Intranasal Single-use intranasal spray *MDV = multidose vials containing ≤25 ug/0.5 mL thimerosal; † Contraindicated only if history of severe allergic reaction (eg, anaphylaxis) to egg; ‡ Precautions in individuals with asthma or underlying medical conditions that may predispose to complications after wild-type influenza infection. IIV3 = inactivated influenza vaccine, trivalent; IIV4 = inactivated influenza vaccine, quadrivalent; IM = intramuscular; LAIV4 = Live attenuated influenza vaccine; RIV4 = recombinant influenza vaccine, quadrivalent. Grohskopf LA, et al. MMWR Recomm Rep. 2020;69:1-24. 9

  10. Vaccine Composition: 2020-2021 Influenza Season Egg-based influenza vaccines (ie, vaccines Cell culture-based inactivated (ccIIV4) and other than ccIIV4 and RIV4) will contain HA recombinant (RIV4) influenza vaccines will derived from: contain HA derived from: Influenza A/Guangdong-Maonan/SWL1536/2019 Influenza A/Hawaii/70/2019 (H1N1)pdm09-like (H1N1)pdm09-like virus virus Influenza A/Hong Kong/2671/2019 (H3N2)-like Influenza A/Hong Kong/45/2019 (H3N2)-like virus virus Influenza B/Washington/02/2019 (Victoria Influenza B/Washington/02/2019 (Victoria lineage)-like virus lineage)-like virus Influenza B/Phuket/3073/2013 (Yamagata Influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus (for quadrivalent vaccines only) lineage)-like virus ACIP = Advisory Committee on Immunization Practices. 10 Grohskopf LA, et al. MMWR Recomm Rep . 2020;69:1-24.

  11. Case Study (cont’d): Victor • Returns to your office in early December after sudden onset of symptoms the previous morning ⎻ Fever (101.8 ° F), chills, body aches, intense headache, extreme fatigue, cough • Missed work today and yesterday • Several coworkers have been sick with flu-like illness • Influenza and COVID-19 are highly prevalent in the community • 3 days earlier, Victor babysat his 4-year-old grandson who was having some head congestion and coughing • Wife, aged 57 years, has not been vaccinated 11 11 11

  12. Influenza Symptoms and Clinical Course • • Classic flu Complications – – Abrupt onset of fever, chills, myalgia, Sinusitis, otitis media headache, fatigue, nonproductive cough, – Pneumonia — primary viral or secondary bacterial sore throat, rhinitis – Coinfections with other bacterial/viral pathogens – Some people may have GI symptoms – Exacerbation of underlying medical conditions (eg, nausea, diarrhea) (eg, COPD, asthma, cystic fibrosis, diabetes) – Typically resolves within 3 to 7 days – Associations with cardiovascular events (eg, MI, – Cough, malaise can persist for >2 weeks stroke), parotitis • Mild illness without fever may also occur • Atypical presentations may occur in elderly, immunocompromised hosts, infants MI = myocardial infarction. Centers for Disease Control and Prevention. cdc.gov/flu/symptoms/symptoms.htm. Accessed Nov 2, 2020; Kwong JC, et al. N Engl J Med . 2018;378:345-353; Rolfes MA, et al. Clin Infect Dis . 2018;67:485-492; Uyeki TM, et al. Clin Infect Dis . 2019;68:895-902. 12

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend